Neal Flomenberg Sells 88,519 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 88,519 shares of Tevogen Bio stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $1.10, for a total value of $97,370.90. Following the sale, the insider now owns 4,040,485 shares in the company, valued at $4,444,533.50. This represents a 2.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neal Flomenberg also recently made the following trade(s):

• On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The shares were sold at an average price of $1.28, for a total value of $18,737.92.

Tevogen Bio Trading Up 3.6 %

Shares of NASDAQ:TVGN opened at $1.14 on Friday. The stock has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.16. Tevogen Bio Holdings Inc. has a 12-month low of $0.26 and a 12-month high of $7.61.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after buying an additional 107,566 shares during the last quarter. HGC Investment Management Inc. purchased a new position in shares of Tevogen Bio in the third quarter worth $82,000. Northern Trust Corp raised its stake in shares of Tevogen Bio by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after purchasing an additional 13,595 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Tevogen Bio in the fourth quarter worth $55,000. Finally, Barclays PLC raised its stake in shares of Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after purchasing an additional 12,847 shares during the last quarter.

Analyst Ratings Changes

Separately, D. Boral Capital assumed coverage on Tevogen Bio in a research note on Tuesday, March 4th. They set a “buy” rating and a $10.00 price objective for the company.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.